SOURCE: MorphoSys AG

November 15, 2010 09:16 ET

MorphoSys to Host R&D Days and Present at Three Investor Conferences in November

MUNICH, GERMANY--(Marketwire - November 15, 2010) -

MorphoSys AG / MorphoSys to Host R&D Days and Present at Three Investor Conferences in November Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at the following upcoming conferences in November, as well as hosting an R&D Day in both London and New York City.

Commerzbank Corporate Day
Date: November 16, 2010 (1-on-1 meetings only, no corporate presentation)
Venue: London, UK
Presenter: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications
& IR

WestLB Deutschland Conference
Date: November 17, 2010 at 10:15am CET (9:15am GMT; 4:15am EST)
Venue: Frankfurt, Germany
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG

Deutsches Eigenkapitalforum
Date: November 23, 2010 at 2:15pm CET (1:15pm GMT; 8:15am EST)
Venue: Frankfurt, Germany
Presenter: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications
& IR

MorphoSys R&D Day 2010 - Europe
Date: November 25, 2010 at 9:30am GMT (10:30am CET; 4:30am EST)
Venue: Berenberg, 60 Threadneedle Street, London, EC2R 8HP, UK

MorphoSys R&D Day 2010 - USA
Date: November 29, 2010 at 11:30am EST (5:30pm CET; 4:30pm GMT)
Venue: The W Hotel, 541 Lexington Avenue, New York, NY 10022, USA

The PDF versions and, if available, live and archived webcasts of the presentations will be provided at

About MorphoSys: MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Conference Announcement:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Löser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact